Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Emerging Team Grant: From Genes to Proteins, Cells, Tissues and Patients - LOI

Memorial University of Newfoundland

$0.00

The Genomics and Proteomics of TMEM43, its association with Arrythmogenic Right Ventricular Cardiomyopathy and the translation of this knowledge to improve the health care of those affected.

FY 2008-09

Summary
The application represents a unique opportunity to capitalize on a Canadian discovery of the TMEM43 gene causing an autosomal dominant form of sudden cardiac death in 15 multiplex ARVC (Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia type-5) families from the Newfoundland founder population in the lab of the nominated Principal Investigator (Merner, et al, 2008; US patent pending). This is the first association of the TMEM43 gene with human disease and the most significant discovery in ARVC research in recent years. The first ARVC gene (plakoglobin) was isolated in 2001 in an autosomal recessive form of ARVC (Naxos disease). Plakoglobin is a desmosomal protein, and this finding directed future functional candidate approaches so that subsequent ARVC genes encode desmosomal proteins. This "looking under the lamppost" approach has limited our view of ARVC and cardiomyopathies in general. The TMEM43 gene (ARVD5) represents an opportunity for a broader exploration as the protein has no homology to desmosomal proteins and may function upstream of a final common pathway. ARVC is a well recognized condition and an important cause of morbidity and mortality. In particular ARVC is a significant cause of sudden cardiac death especially among young people. Of late it has been recognized that this condition can result from different genetic mutations in multiple genes. Unfortunately, the clinical diagnosis of this condition is difficult. Currently published Task Force criteria are employed as the "gold standard". However it is likely that this condition has both a "concealed" phase followed by a more "manifest" phase when typical clinical tests begin to demonstrate abnormality. Unfortunately during the "concealed" phase when there is very little macroscopic structural cardiac abnormality lethal ventricular arrhythmia may occur. This observation demonstrates the direct clinical impact improved diagnostic mechanisms will have on patients with ARVC.
Program
Emerging Team Grant: From Genes to Proteins, Cells, Tissues and Patients - LOI
Location
Newfoundland and Labrador, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
174406
Name
Young Terry-Lynn
Region
Newfoundland and Labrador
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Emerging Team Grant: From Genes to Proteins, Cells, Tissues and Patients
Projecttitle
The Genomics and Proteomics of TMEM43, its association with Arrythmogenic Right Ventricular Cardiomyopathy and the translation of this knowledge to improve the health care of those affected.
Programtype2
Operating Grants
Orgnameinp2
Memorial University of Newfoundland
Cihramount2
$0
Cihrequipment2
$0
Programname2
Emerging Team Grant: From Genes to Proteins, Cells, Tissues and Patients - LOI
Keyworddelim
Animal Model Mechanisms; Arrythmogenic Right Ventricular Cardiomyopathy; Ge3ls; Proteins; Tmem43; Translational Research
Abstract
The application represents a unique opportunity to capitalize on a Canadian discovery of the TMEM43 gene causing an autosomal dominant form of sudden cardiac death in 15 multiplex ARVC (Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia type-5) families from the Newfoundland founder population in the lab of the nominated Principal Investigator (Merner, et al, 2008; US patent pending). This is the first association of the TMEM43 gene with human disease and the most significant discovery in ARVC research in recent years. The first ARVC gene (plakoglobin) was isolated in 2001 in an autosomal recessive form of ARVC (Naxos disease). Plakoglobin is a desmosomal protein, and this finding directed future functional candidate approaches so that subsequent ARVC genes encode desmosomal proteins. This "looking under the lamppost" approach has limited our view of ARVC and cardiomyopathies in general. The TMEM43 gene (ARVD5) represents an opportunity for a broader exploration as the protein has no homology to desmosomal proteins and may function upstream of a final common pathway. ARVC is a well recognized condition and an important cause of morbidity and mortality. In particular ARVC is a significant cause of sudden cardiac death especially among young people. Of late it has been recognized that this condition can result from different genetic mutations in multiple genes. Unfortunately, the clinical diagnosis of this condition is difficult. Currently published Task Force criteria are employed as the "gold standard". However it is likely that this condition has both a "concealed" phase followed by a more "manifest" phase when typical clinical tests begin to demonstrate abnormality. Unfortunately during the "concealed" phase when there is very little macroscopic structural cardiac abnormality lethal ventricular arrhythmia may occur. This observation demonstrates the direct clinical impact improved diagnostic mechanisms will have on patients with ARVC.
Competitiondate
200810
Approvedterm2
1 yr 0 mth
Pinamesdelim
Young, Terry-Lynn; Connors, Sean P; Parfrey, Patrick S; Pullman, Daryl; Stuyvers, Bruno
Approvedterm
1 an 0 mois